Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GENIZ will receive a $12.5 million up front payment, and can achieve annual milestone payments of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury